Meridian Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Withdraws registration statement filed with the Securities and Exchange Commission for the proposed sale of 2 mil. shares of common stock, citing "unsettled market conditions affecting companies related to the health care industry." The Cincinnati immunodiagnostic firm's chairman, William Motto, said in a July 29 press release that the firm "was unwilling to sell shares at a price level which failed to recognize the company's record of growth and its expectations".
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.